Introduction
The discovery of leptin is a prime example of the contributions that molecular biology can make to further our understanding of mechanisms hypothesized in classic physiological studies. 1 Leptin is produced in adipose tissue and regulates the secretion of many neuroendocrines. Plasma leptin concentrations are reduced in people who die from sepsis compared to those who survive, 2 and this may indicate the importance of leptin levels. Decreased leptin concentrations may deteriorate the development of cardiac adaptation. 3 Studies have focused on the associations between plasma leptin levels and aspects of the cardiovascular system such as hypertension. 4 Others have shown that plasma leptin levels are low in patients with cachexia and chronic heart failure. 5 However, plasma leptin levels have not been studied previously in patients with acute myocardial infarction (AMI 
Materials and methods

PATIENTS
We evaluated plasma leptin levels in 21 Japanese patients with AMI (15 men and six women, age range 55 -77 years). All patients had been admitted to hospital with suspected AMI, within 6 h of symptom onset. The final diagnosis of AMI was based on the presence of chest pain that persisted for at least 30 min, ST-segment elevations > 0.2 mV in at least two contiguous leads, and elevation of the serum creatine kinase concentration to twice the upper limit of normal (> 250 IU/l).
Angina pectoris was defined as typical chest pain at rest with at least two episodes occurring in the previous 48 h or one episode lasting > 20 min, ST-segment deviations diagnostic of myocardial ischaemia during angina, or an episode of chest pain within the previous 24 h with no elevation in serum creatine kinase (< 250 IU/l).
As control subjects we used 15 patients who underwent cardiac catheterization and coronary angiography and who had no evidence of coronary stenosis or coronary spasm. No patient or control subject had septicaemia, collagen disease, advanced liver disease, renal failure, malignant disease or an infectious disease.
BLOOD SAMPLES
Blood was sampled immediately on hospital admission, at 1 h, 2 h, 3 h, 6 h, 9 h and every 12 h subsequently until 5 days postadmission. We analysed correlations between peak plasma leptin and other markers of AMI (listed below) to determine the effect of hypoleptinaemia on myocardial parameters.
Serum creatine phosphokinase, aspartate aminotransferase, plasma lactate dehydrogenase (LDH) and leukocyte counts were measured using an autoanalyser (Shionoria ANP Kit SRL, Japan). Human atrial natriuretic peptide levels were measured by radioimmunoassay autoanalyser (Shionoria ANP Kit SRL). Left ventricular ejection fraction was assessed using the M mode of echocardiography (Toshiba SSH-65A System, Japan) between days 3 and 5 (median, day 3) after AMI onset. Plasma leptin concentrations were measured using a commercial radioimmunoassay autoanalyser (Linco Research Inc, USA). 6 Plasma concentrations of interleukin (IL)-6 were measured using a cheminolucent enzyme immunoassay kit (Fujirebio, Japan).
We divided patients into three groups based on the peak leptin concentration measured. The groups were defined as hypoleptinaemia (< 3 ng/ml), normoleptinaemia (≥ 3 -< 15 ng/ml), and hyperleptinaemia (≥ 15 ng/ml).
STATISTICAL ANALYSIS
One-way ANOVA statistical analyses were performed. P-values of < 0.05 were considered to be statistically significant.
Results
Plasma leptin and myocardial enzyme profiles were available for all 21 AMI patients and 15 matched controls (Table 1) .
LEPTIN IN AMI
Hypoleptinaemic AMI patients had significantly increased LDH concentrations compared with normoleptinaemic patients (P < 0.01, Table 1 ). No significant differences were observed in other blood markers between hyperleptinaemic and normoleptinaemic AMI patients. The time-course of plasma leptin concentrations in hypoleptinaemic and normoleptinaemic patients is shown in Fig. 1 . Patients with peak plasma leptin ≥ 3 ng/ml -< 15 ng/ml Patients with peak plasma leptin < 3 ng/ml 
S Fujimaki, T Kanda, K Fujita et al. Plasma leptin in acute myocardial infarction
Leptin concentrations peaked in normoleptinaemic patients 12 -24 h post-AMI symptom onset, but did not peak in hypoleptinaemic patients until 72 h post-AMI. Table 2 shows the maximal rise and value of plasma leptin in AMI patients. Other markers of AMI, such as leukocyte count, myoglobin and the creatine kinase-MB isoform are also shown and compared with leptin. Levels of these markers peaked earlier than leptin.
LEPTIN AND SERUM MARKERS
PLASMA LEPTIN CONCENTRATIONS
A significant negative correlation was observed between peak leptin and IL-6 concentrations (r = -0.39, P < 0.05; Fig. 2 ). The peak leptin concentration did not correlate significantly with left ventricular ejection fraction (Fig. 2 ).
Discussion
We have demonstrated that plasma leptin concentrations peaked at 23 ± 9 h after AMI onset. Patients in our study who had AMI S Fujimaki, T Kanda, K Fujita et al. Plasma leptin in acute myocardial infarction and peak leptin concentrations < 3 ng/ml had significantly greater plasma LDH concentrations compared with normoleptinaemic patients. Moreover, we observed a significant negative correlation between peak plasma leptin and IL-6 concentrations. Patients with reduced leptin secretion may lack the ability to regulate cardiac homeostasis in the development of AMI.
Other studies have focused on the associations between leptin and the cardiovascular system. 4, 5 Hyperleptinaemia and elevated blood pressure have been observed in the healthy offspring of patients with essential hypertension 4 and plasma leptin levels have been demonstrated to be inappropriately low in patients with cachectic chronic heart failure. 5 In addition, adrenergic activation is known as a contributor to leptin regulation in humans. 7 Leptin may act as both a satiety factor and a mediator which increases haemodynamic effects.
The pro-inflammatory cytokine IL-6 plays a key role in the pathogenesis of coronary artery disease 8 and plasma IL-6 elevations portend a poor prognosis in patients with congestive heart failure. 9 Therefore, it is feasible that IL-6 may be involved in the pathogenesis of myocardial dysfunction. Within 24 h of symptom onset in patients with AMI, IL-6 concentrations are reported to increase, and levels peak around day 3 post-AMI. 10, 11 Our previous autopsy study demonstrated increased IL-6 expression in the injured myocardium with the first 7 days post-AMI, peaking 3 -4 days after symptom onset. 12 Although plasma leptin levels increase in obese patients, a relative underproduction of leptin has been postulated in these patients. 13 We found that circulating leptin peaks at 23 ± 9 h after the onset of AMI, but the mechanism of leptin production is not known. The negative correlation that we identified between plasma IL-6 and leptin levels suggests that such reductions in plasma leptin may indicate impairment of adaptational mechanisms that support homeostasis in patients with AMI, via adrenergic activation to regulate blood pressure. The cumulative release of LDH has been utilized as a measure of infarct size in patients with AMI. 14 We demonstrated that hypoleptinaemic patients with AMI had a significantly increased LDH release compared with normoleptinaemic patients.
Other markers did not correlate with plasma leptin concentration, however. Patients with severe infarction have more deranged cardiac haemodynamics and have decreased food intake and increased energy expenditure, 15 a combination that can reduce leptin secretion. Overactivity of the sympathetic nervous system induced by severe heart failure due to AMI 16 could also explain changes in plasma leptin concentration, because sympathetic nerve hyperactivity decreases leptin release in vitro and in vivo 17, 18 and isoproterenol, betaadrenergic agonist, and somatostatin decrease plasma leptin levels in humans. 19 The hypoleptinaemic patient with AMI may be in a hyperadrenergic state. Further studies will be necessary to examine this hypothesis.
Recombinant leptin therapy has already been used in congenital leptin deficiency. 20 Leptin has furthered our understanding of the mechanisms underlying cardiac function. Elucidation of these mechanisms is expected to result in the development of novel therapeutic approaches aimed at the regulation of cardiac homeostasis in AMI. 
